Cetirizine Hydrochloride 10mg Tablets
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Cetirizine Hydrochloride 10 mg tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains Cetirizine hydrochloride 10 mg.
Excipient: This product contains 101.83 mg lactose per tablet For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Film-coated tablet (tablets).
White circular biconvex film-coated tablets, embossed ‘A’ on one side and a deep score on the other.
The tablet can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
In adults and paediatric patients 6 years and above:
- Cetirizine is indicated for the relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis.
- Cetirizine is indicated for the relief of symptoms of chronic idiopathic urticaria.
4. CLINICAL PARTICULARS
4.2. Posology and Method of Administration
Children aged from 6 to 12 years: 5 mg twice daily (a half tablet twice daily).
Adults and adolescents over 12 years of age: 10 mg once daily (1 tablet).
Older people: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function is normal.
Patients with moderate to severe renal impairment: there are no data to document the efficacy/safety ratio in patients with renal impairment. Since cetirizine is mainly excreted via renal route (see section 5.2), in cases no alternative treatment can be used, the dosing intervals must be individualized according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient’s creatinine clearance (CLcr) in ml/min is needed. The CLcr (ml/min) may be estimated from serum creatinine (mg/dl) determination using the following formula:
CLcr = [140 - age (years)] x weight (kg)
_ (x 0.85 for women) 72 x serum creatinine (mg / dl)
Dosing adjustments for adult patients with impaired renal function
|
Group |
Creatinine clearance (ml/min) |
Dosage and frequency |
|
Normal |
>80 |
10 mg once daily |
|
Mild |
50 - 79 |
10 mg once daily |
|
Moderate |
30 - 49 |
5 mg once daily |
|
Severe |
<30 |
5 mg once every 2 days |
|
End-stage renal disease - |
<10 |
Contra-indicated |
In paediatric patients suffering from renal impairment, the dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient, his age and his body weight.
Patients with hepatic impairment: no dose adjustment is needed in patients with solely hepatic impairment.
Patients with hepatic impairment and renal impairment: dose adjustment is recommended (see Patients with moderate to severe renal impairment above).
The tablets need to be swallowed with a glass of liquid.
4. CLINICAL PARTICULARS
4.3. Contraindications
Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, to hydroxyzine or to any piperazine derivatives.
Patients with severe renal impairment at less than 10 ml/min creatinine clearance.
4.
CLINICAL PARTICULARS
4.4. Special Warnings and Precautions for use
At therapeutic doses, no clinically significant interactions have been demonstrated with alcohol (for a blood alcohol level of 0.5 g/L). Nevertheless, precaution is recommended if alcohol is taken concomitantly.
Caution should be taken in patients with predisposition factors of urinary retention (e.g. spinal cord lesion prostatic hyperplasia) as cetirizine may increase the risk of urinary retention.
Caution in epileptic patients and patients at risk of convulsions is recommended.
Allergy skin tests are inhibited by antihistamines and a washout period (of 3 days) is required before performing them.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Paediatric population
The use of the film-coated tablet formulation is not recommended in children aged less than 6 years since this formulation does not allow for appropriate dose adaptation.
4. CLINICAL PARTICULARS
4.5. Interactions with Other Medicinal Products and Other Forms of Interaction
Due to the pharmacokinetic, pharmacodynamic and tolerance profile of cetirizine, no interactions are expected with this antihistamine. Actually, neither pharmacodynamic nor significant pharmacokinetic interaction was reported in drug-drug interactions studies performed, notably with pseudoephedrine or theophylline (400 mg/day).
The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased.
The concurrent use of alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance, although cetirizine does not potentiate the effects of alcohol (0.5g/L blood levels).
4. CLINICAL PARTICULARS
4.6. Fertility, Pregnancy and Lactation
Pregnancy
For cetirizine, prospectively collected data on pregnancy outcomes do not suggest potential for maternal or foteal/embryonic toxicity above background rates. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women.
Breast Feeding
Cetirizine is excreted in human milk at concentrations representing 25% to 90% of those measured in plasma, depending on sampling time after administration.
Therefore, caution should be exercised when prescribing to lactating women.
Fertility
Limited data is available on human fertility but no safety concern has been identified. Animal data show no safety concern for human reproduction.
4. CLINICAL PARTICULARS
4.7. Effects on Ability to Drive and Use Machines
Objective measurements of driving ability, sleep latency and assembly line performance have not demonstrated any clinically relevant effects at the recommended dose of 10 mg. Patients intending to drive, engaging in potentially hazardous activities or operating machinery should not exceed the recommended dose and should take their response to the medicinal product into account.
4. CLINICAL PARTICULARS
4.8. Undesirable Effects
Clinical studies have shown that cetirizine at the recommended dosage has minor undesirable effects on the CNS, including somnolence, fatigue, dizziness and headache. In some cases, paradoxical CNS stimulation has been reported.
Although cetirizine is a selective antagonist of peripheral H1-receptors and is relatively free of anticholinergic activity, isolated cases of micturition difficulty, eye accommodation disorders and dry mouth have been reported.
Instances of abnormal hepatic function with elevated hepatic enzymes accompanied by elevated bilirubin have been reported. Mostly this resolves upon discontinuation of the treatment with cetirizine dihydrochloride
Clinical trials
Double blind controlled clinical trials comparing cetirizine to placebo or other antihistamines at the recommended dosage (10 mg daily for cetirizine), of which quantified safety data are available, included more than 3200 subjects exposed to cetirizine. From this pooling, the following adverse reactions were reported for cetirizine 10 mg in the placebo-controlled trials at rates of 1.0 % or greater:
|
Adverse event (WHO-ART) |
Cetirizine 10 mg (n= 3260) |
Placebo (n = 3061) |
|
General disorders and administration site conditions: |
1.63 % |
0.95 % |
|
Nervous system disorders: | ||
|
Dizziness |
1.10 % |
0.98 % |
|
Headache |
7.42 % |
8.07 % |
|
Gastro-intestinal system disorders: Abdominal pain Dry mouth Nausea |
0.98 % |
1.08 % |
|
2.09 % |
0.82 % | |
|
1.07 % |
1.14 % | |
|
Psychiatric disorders: Somnolence |
9.63 % |
5.00 % |
|
Respiratory, thoracic and mediastinal disorders: |
1.29 % |
1.34 % |
Although statistically more common than under placebo, somnolence was mild to moderate in the majority of cases. Objective tests as demonstrated by other studies have demonstrated that usual daily activities are unaffected at the recommended daily dose in healthy young volunteers.
Adverse drug reactions at rates of 1 % or greater in children aged from 6 months to 12 years, included in placebo-controlled clinical or pharmacoclinical trials are:
|
Adverse drug reactions (WHO-ART) |
Cetirizine (n=1656) |
Placebo (n =1294) |
|
Gastrointestinal disorders: Diarrhoea |
1.0 % |
0.6 % |
|
Psychiatric disorders: Somnolence |
1.8 % |
1. 4 % |
|
Respiratory, thoracic and mediastinal disorders: |
1.4 % |
1.1 % |
|
General disorders and administration site conditions: |
1.0 % |
0.3 % |
Post-marketing experience
In addition to the adverse reactions reported during clinical studies and listed above, the following undesirable effects have been reported in post-marketing experience. Undesirable effects are described according to the MedDRA System Organ Class and by estimated frequency based on post-marketing exposure. Frequencies are defined as follows: Very common (>1/10); common (>1/100 to 1/10); uncommon (>1/1,000 to 1/100), rare
( >1/10,000 to 1/1,000), very rare (1/10,000); not known (cannot be estimated from the available data).
Blood and lymphatic disorders:
Very rare: thrombocytopenia
Immune system disorders:
Rare: hypersensitivity
Very rare: anaphylactic shock
Metabolic and nutritional disorders:
Not known: increased appetite
Psychiatric disorders: Uncommon:
Rare:
Very rare:
Not known:
agitation
aggression, confusion, depression, hallucination, insomnia tics
Suicidal ideation
Nervous system disorders:
Uncommon: paraesthesia
Rare: convulsions, movement disorders
Very rare: dysgeusia, syncope, tremor, dystonia, dyskinesia
Not known: amnesia, memory impairment
Eye disorders: Very rare:
accommodation disorder, blurred vision, oculogyration
Ear and labyrinth disorders:
Not known: vertigo
Cardiac disorders:
Rare: tachycardia
Gastro-intestinal disorders:
Uncommon: diarrhoea
Hepatobiliary disorders:
Rare: hepatic function abnormal (increased transaminases, alkaline
phosphatase, y- GT and bilirubin)
Skin and subcutaneous tissue disorders:
Uncommon: pruritus, rash
Rare: urticaria
Very rare: angioneurotic oedema, fixed drug eruption
Renal and urinary disorders:
Very rare: dysuria, enuresis
Not known: urinary retention
General disorders and administration site conditions:
Uncommon: asthenia, malaise
Rare: oedema
Investigations:
Rare: weight increased
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the yellow card system at www.mhra.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.
4. CLINICAL PARTICULARS
4.9. Overdose
Symptoms
Symptoms observed after an overdose of cetirizine are mainly associated with CNS effects or with effects that could suggest an anticholinergic effect. Adverse events reported after an intake of at least 5 times the recommended daily dose are: confusion, diarrhoea, dizziness, fatigue, headache, malaise, mydriasis, pruritus, restlessness, sedation, somnolence, stupor, tachycardia, tremor, and urinary retention.
Management
There is no known specific antidote to cetirizine. Should overdose occur, symptomatic or supportive treatment is recommended. Gastric lavage should be considered following ingestion of a short occurrence. Cetirizine is not effectively removed by haemodialysis.
5. PHARMACOLOGICAL PROPERTIES
5.1. Pharmacodynamic Properties
Pharmacotherapeutic group: Antihistamine for systemic use, piperazine derivatives, ATC code: R06 AE07
Mechanism of action
Cetirizine, a human metabolite of hydroxyzine, is a potent and selective antagonist of peripheral H1receptors. In vitro receptor binding studies have shown no measurable affinity for other than H1-receptors.
Pharmacodynamic effects
In addition to its anti-H1 effect, cetirizine was shown to display anti-allergic activities: at a dose of 10 mg once or twice daily, it inhibits the late phase recruitment of eosinophils, in the skin and conjunctiva of atopic subjects submitted to allergen challenge.
Clinical efficacy and safety
Studies in healthy volunteers show that cetirizine, at doses of 5 and 10 mg strongly inhibits the wheal and flare reactions induced by very high concentrations of histamine into the skin, but the correlation with efficacy is not established.
In a six-week, placebo-controlled study of 186 patients with allergic rhinitis and concomitant mild to moderate asthma, cetirizine 10 mg once daily improved rhinitis symptoms and did not alter pulmonary function. This study supports the safety of administering cetirizine to allergic patients with mild to moderate asthma.
In a placebo-controlled study, cetirizine given at the high daily dose of 60 mg for seven days did not cause statistically significant prolongation of QT interval.
At the recommended dosage, cetirizine has demonstrated that it improves the quality of life of patients with perennial and seasonal allergic rhinitis
Paediatric population
In a 35-day study in children aged 5 to 12, no tolerance to the antihistaminic effect (suppression of wheal and flare) of cetirizine was found. When a treatment with cetirizine is stopped after repeated administration, the skin recovers its normal reactivity to histamine within 3 days.
5. PHARMACOLOGICAL PROPERTIES
5.2. Pharmacokinetic Properties
Absorption
The steady - state peak plasma concentration is approximately 300 ng/ml and is achieved within 1.0 ± 0.5 h. No accumulation is observed for cetirizine following daily doses of 10 mg for 10 days. The distribution of pharmacokinetic parameters, such as peak plasma concentration (Cmax) and area under curve (AUC), is unimodal in human volunteers. The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased. The extent of bioavailability is similar when cetirizine is given as solutions, capsules or tablets.
Distribution
The apparent volume of distribution is 0.50 l/kg. Plasma protein binding of cetirizine is 93 ± 0.3 %. Cetirizine does not modify the protein binding of warfarin.
Biotransformation
Cetirizine does not undergo extensive first pass metabolism.
Linearity/non-linearity
The terminal half life is approximately 10 hours and no accumulation is observed for cetirizine following daily doses of 10mg for 10 days. About two thirds of the dose are excreted unchanged in urine.
Cetirizine exhibits linear kinetics over the range of 5 to 60 mg.
Special populations
Older people : Following a single 10 mg oral dose, half-life increased by about 50 % and clearance decreased by 40 % in 16 elderly subjects compared to the normal subjects. The decrease in cetirizine clearance in these elderly volunteers appeared to be related to their decreased renal function.
Paediatric population: The half-life of cetirizine was about 6 hours in children of 612 years and 5 hours in children 2-6 years. In infants and toddlers aged 6 to 24 months, it is reduced to 3.1 hours
Renally impaired: The pharmacokinetics of the drug were similar in patients with mild impairment (creatinine clearance higher than 40 ml/min) and healthy volunteers. Patients with moderate renal impairment had a 3-fold increase in half-life and 70 % decrease in clearance compared to healthy volunteers.
Patients on hemodialysis (creatinine clearance less than 7 ml/min) given a single oral 10 mg dose of cetirizine had a 3-fold increase in half-life and a 70 % decrease in clearance compared to normals. Cetirizine was poorly cleared by haemodialysis. Dosing adjustment is necessary in patients with moderate or severe renal impairment (see section 4.2).
Hepatically impaired: Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10 or 20 mg of cetirizine as a single dose had a 50 % increase in half-life along with a 40 % decrease in clearance compared to healthy subjects. Dosing adjustment is only necessary in hepatically impaired patients if concomitant renal impairment is present.
5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose Monohydrate
Microcrystalline Cellulose Maize Starch
Colloidal Anhydrous Silica Magnesium Stearate Talc
Film coat contains:
Hypromellose Lactose monohydrate Titanium Dioxide E171 Macrogol 4000 Sodium Citrate
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
Three years.
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
Blister strips composed of transparent PVC and aluminium foil.
Pack sizes: 7 tablets
Special precautions for disposal
6.6
7
No special requirements.
MARKETING AUTHORISATION HOLDER
Aspar Pharmaceuticals Limited 29 - 30 Capitol Way Colindale
London NW9 0EQ,
United Kingdom.
8
9
MARKETING AUTHORISATION NUMBER(S)
PL 08977/0046
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
30/06/2011
DATE OF REVISION OF THE TEXT
20/04/2016